{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:30:59Z","timestamp":1782307859833,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bneo.2025.100171","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:57:25Z","timestamp":1760075845000},"page":"100171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML"],"prefix":"10.1016","volume":"3","author":[{"given":"Jayanshu","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1932-6209","authenticated-orcid":false,"given":"Shivani","family":"Handa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn M.","family":"Dvorak-Kornaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-9466","authenticated-orcid":false,"given":"Jennifer","family":"Saultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Swords","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-2659","authenticated-orcid":false,"given":"George S.","family":"Laszlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Grieselhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-2199","authenticated-orcid":false,"given":"Alice S.","family":"Mims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-9836","authenticated-orcid":false,"given":"Karilyn T. M.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Sahasrabudhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-5562","authenticated-orcid":false,"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-3607","authenticated-orcid":false,"given":"Gregory K.","family":"Behbehani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Eisfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0820-5612","authenticated-orcid":false,"given":"Meixiao","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8736-8726","authenticated-orcid":false,"given":"Andrew","family":"Srisuwananukorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2071-3169","authenticated-orcid":false,"given":"Kristin L.","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.bneo.2025.100171_bib1","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bneo.2025.100171_bib2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","article-title":"Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome","volume":"114","author":"Kayser","year":"2009","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2025.100171_bib3","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study","volume":"61","author":"Whitman","year":"2001","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2025.100171_bib4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10388","key":"10.1016\/j.bneo.2025.100171_bib5","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-first): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bneo.2025.100171_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-023-00839-1","article-title":"Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort","volume":"13","author":"O\u00f1ate","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.bneo.2025.100171_bib7","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.bneo.2025.100171_bib8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100171_bib9","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"issue":"9825","key":"10.1016\/j.bneo.2025.100171_bib10","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study [Erratum in: Lancet. 2018;391(10123):838]","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bneo.2025.100171_bib11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100171_bib12","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/1078-0432.CCR-15-1349","article-title":"Gemtuzumab ozogamicin reduces relapse risk in FLT3\/ITD acute myeloid leukemia: a report from the Children's Oncology Group","volume":"22","author":"Tarlock","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.bneo.2025.100171_bib13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2022-157126","article-title":"Single versus double induction with \u201c7+3\u201d containing 60 versus 90 mg daunorubicin for newly diagnosed AML: results from the randomized controlled SAL Dauno-Double trial","volume":"140","author":"R\u00f6llig","year":"2022","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2025.100171_bib14","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1158\/1078-0432.CCR-17-0220","article-title":"Keyboard: a novel Bayesian toxicity probability interval design for phase I clinical trials","volume":"23","author":"Yan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9825","key":"10.1016\/j.bneo.2025.100171_bib15","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bneo.2025.100171_bib16","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3324\/haematol.2022.282263","article-title":"Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience","volume":"108","author":"Weinbergerov\u00e1","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bneo.2025.100171_bib17","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/bjh.19436","article-title":"Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: results from the SAL-MODULE phase I study","volume":"204","author":"R\u00f6llig","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bneo.2025.100171_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.HS9.0000843396.14484.b9","article-title":"Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Results from the NCRI AML19 \u201cMIDOTARG\u201d pilot trial [abstract]","volume":"6","author":"Russell","year":"2022","journal-title":"HemaSphere"},{"issue":"23","key":"10.1016\/j.bneo.2025.100171_bib19","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children's Oncology Group trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100171_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2017-08-802157","article-title":"No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC\/NCRI trials","volume":"131","author":"Gale","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100171_bib21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100171_bib22","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:49:08Z","timestamp":1771465748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2950328025001062"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100171","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100171"}}